20 results about "Viral envelope" patented technology

Provided is a viral vector having a lipid bilayer envelope, the lipid bilayer envelope comprising an antibody binding domain displayed outside the envelope, the antibody binding domain being cell type specific; a viral envelope protein exhibited outside the envelope, the viral envelope protein being capable of promoting infection of the same cell type; and a nucleic acid molecule comprising a promoter capable of being expressed in the same cell type. Methods of making the viral vectors and methods of modifying cells and treating diseases / conditions using the viral vectors are also provided.

Disclosed herein are compositions and methods for determining the structure of a membrane protein. An epitope from a membrane-proximal external region (MPER) from a viral envelope protein can be grafted on to a variety of diverse membrane proteins to allow for binding structurally characterized antibody fragments, which can aid structural studies.

The present disclosure relates to a novel vaccine strategy against hepatitis B virus (HBV) infection, which is a major cause of chronic liver disease and hepatocellular carcinoma worldwide. The disclosure provides fusion proteins that target dendritic cells (DCs), the key antigen-presenting cells of the immune system, and deliver HBV-derived peptides to both the major histocompatibility complex (MHC) class I and II pathways, thereby inducing strong and specific humoral and cellular immune responses against the viral envelope and core antigens. The disclosure also provides methods of using the fusion proteins for the prevention or treatment of HBV infection and its complications. The inventors have demonstrated in a mouse model that the DC-targeting HBV vaccine candidates can elicit robust antibody and T cell responses, which are essential for the clearance of the virus and the protection from chronic infection.

A viral vector having a lipid bilayer envelope is provided, comprising a cell-type specific antibody-binding domain presented outside the envelope, a viral envelope protein presented outside the envelope capable of promoting infection of the same cell type, and a nucleic acid molecule containing a promoter expressible in the same cell type. Furthermore, a method for producing the viral vector and a method for modifying cells and treating diseases / conditions using this viral vector are also provided.

The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises: (i) a mitogenic T-cell activating transmembrane protein which comprises a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T-cell activating transmembrane protein which comprises a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells of Natural Killer cells are transduced by such a viral vector, they are simultaneously activated by the mitogenic T-cell activating transmembrane protein and / or the cytokine-based T-cell activating transmembrane protein.

Provided are a targeting vector and a method for targeting same to a host cell. The vector comprises a first molecule that binds to an endocytosis receptor of the target cell and a second molecule that promotes the release of a substance carried by the targeting vector into a cytoplasm. When the targeting vector is a viral vector, the first molecule is not part of a viral envelope protein, and the second molecule promotes endosomal escape or lysosomal escape of the targeting vector. The first molecule is designed according to the endocytosis receptor of the cell to be targeted, different types of cells can be targeted, and after a reasonable mutation is carried out on the vector, infection of cells that do not need to be targeted can be avoided, thereby improving the accuracy of the vector.

The application discloses a CD7 and CD3 double-targeting fusion protein and application thereof. Specifically, the application discloses an isolated fusion protein, which comprises, from N-terminal to C-terminal, (a) an anti-CD7 single-domain antibody (CD7 VHH); (b) an anti-CD3 single-domain antibody (CD3 VHH); and (c) a transmembrane region, which is used for anchoring the fusion protein on a cell membrane or a viral envelope. And a T cell-targeting pseudotyped lentiviral vector based on the fusion protein is constructed. The pseudotyped lentiviral vector of the application can effectively target and activate T cells, and can deliver the expression CAR-containing vector into T cells, thereby effectively activating T cells and enhancing the target killing ability of T cells.

To provide retroviral and lentiviral vectors.SOLUTION: The invention provides a retroviral or lentiviral vector having a viral envelope comprising: (i) a mitogenic T cell activating transmembrane protein comprising a mitogenic domain and a transmembrane domain; and / or (ii) a cytokine-based T cell activating transmembrane protein comprising a cytokine domain and a transmembrane domain, wherein the mitogenic or cytokine-based T cell activating transmembrane protein is not part of the viral envelope glycoprotein. When cells such as natural killer cells are transduced with such viral vectors, they are simultaneously activated by the mitogenic T cell activating transmembrane protein and / or the cytokine-based T cell activating transmembrane protein.SELECTED DRAWING: None

Provided is a pseudotyped viral particle, a viral envelope surface thereof comprising immune cell-targeting molecules and / or immune cell-activating molecules. Corresponding targeting molecules are designed on the basis of cell receptors to be targeted, enabling targeting of different types of cells. The application scope is broad, including but not limited to the rapid preparation of CAR-T, CAR-NK, and other immunotherapeutic cells in vitro without the need for sorting and activation, as well as the direct generation of CAR-T, CAR-NK, and other immunotherapeutic cells in vivo.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

The present disclosure provides enveloped delivery vehicles (EDVs) comprising a nucleic acid-binding effector polypeptide, or a nucleic acid encoding the nucleic acid-binding effector polypeptide, where the EDV comprises a fusion polypeptide comprising (i) a viral envelope protein and (ii) a targeting polypeptide that provides for binding to a target cell. The present disclosure provides methods of using an EDV of the present disclosure for delivery of, e.g., a nucleic acid-binding effector polypeptide, to a eukaryotic cell.

This invention belongs to the field of veterinary biological agent technology, specifically relating to a bacterial-enzyme complex preparation for the prevention and treatment of transmissible gastroenteritis (TGEV) in pigs, its preparation method, and its application. The bacterial-enzyme complex preparation comprises microcapsule particles; the core material of each microcapsule particle includes a complex of probiotics and a synergistic enzyme system; the complex of probiotics includes *Lactobacillus rhamnosus*, *Bacillus coagulans*, *Pediococcus pentosus*, and *Kluyveromyces marsupialis*. In the bacterial-enzyme complex preparation for the prevention and treatment of TGEV provided by this invention, the complex probiotics and the synergistic enzyme system form a synergistic effect. Lactic acid secreted by *Lactobacillus rhamnosus* can lower the intestinal pH, disrupting the TGEV survival environment; antimicrobial peptides produced by *Bacillus coagulans* can directly cleave the viral capsid protein; lysozyme can degrade viral envelope polysaccharides; and neutral protease, β-glucanase, and xylanase can destroy the viral adsorption sites on the intestinal mucosa. This quadruple action significantly enhances the antiviral effect.

The invention relates to a lentiviral vector or retroviral vector and application thereof in infection of B cells, establishment of acquired immunity in subjects and preparation of broad-spectrum neutralizing antibodies. A virus envelope of the lentiviral vector or the retroviral vector contains a targeting molecule targeting B cells and carries a broad-spectrum neutralizing antibody gene; the viral glycoprotein of the lentiviral vector or retroviral vector may further comprise a first mutation that attenuates its ability to bind to a receptor and a second mutation that enhances its ability to antagonize complement inactivation, the capacity of the lentiviral vector or the retroviral vector for targeted transduction of B cells in a subject and preparation of broad-spectrum neutralizing antibodies is further enhanced.

The present application provides novel viral envelope glycoproteins for viral vector pseudotyping, novel designs for synthetic antigen receptors (SARs), novel signal chains for constructing SAR, novel antigen binding domains, and novel methods for generating SAR expressing cells. These novel methods and compositions have broad applications in cell therapy.

The current disclosure includes a modular vaccine platform. Also included are monkeypox vaccines that protect against pathogenic monkeypox (Mpox) species, as well as their variants. The vaccines typically include a modified mRNA encoding at least one immunogen, such as a viral envelope protein, cell surface binding protein, or a biologically effective / significant fragment thereof. The mRNA can be encapsulated into lipid nanoparticles or other carriers and formulated as pharmaceutical compositions that can be used to generate an immune response to pathogens, including monkeypox virus, in a subject.

A pharmaceutical composition with dual anti-inflammatory and antiviral activity against COVID-19 and related respiratory pathogens, the composition comprising the following: (a) Curcumin in an amount of 1.5 to 5.0% by weight, which acts as a primary anti-inflammatory agent, suppressing cyclooxygenase-2 (COX-2) expression and interleukin-6 (IL-6) signaling; b) Quercetin in an amount of 2.0 to 6.0 wt%, which acts as an antiviral flavonoid and is able to inhibit SARS-CoV-2 proteases (3CLpro and PLpro) and the penetration of the virus; (c) Zinc oxide nanoparticles (ZnO-NPs) in an amount of 0.5 to 2.0 wt%, with an average particle size between 20 and 40 nm, which facilitate the destruction of viral envelope proteins and increase cellular zinc uptake; d) Ascorbic acid (vitamin C) in an amount of 1.0 to 4.0 wt.%, which acts as an antioxidant to neutralize reactive oxygen species (ROS) produced during viral infections and inflammatory reactions; (e) Glycyrrhizin, extracted from licorice glabra, in an amount of 1.0 to 3.0% by weight, acts as an immunomodulator, stabilizes cytokine levels and reduces pneumonia; and (f) a pharmaceutically acceptable carrier medium consisting of liposomal, polymeric or PEG-based excipients in an amount of 80 to 90 wt.%, which ensures sustained release and improved bioavailability of the active substances.

The application belongs to the technical field of veterinary drugs and provides a preparation for porcine blue ear disease and African swine fever and a preparation method thereof.The preparation comprises the following raw materials: modified rhizomary peucedani inclusion compound, nano astragalus-houttuynia cordata complex, medium-chain fatty acid glyceride, organic acid sustained-release microcapsule, fermented ammonium glycyrrhizinate, seleniumized isatis indigotica polysaccharide, modified quercetin, modified mannitol and a pharmaceutical carrier.The preparation for porcine blue ear disease and African swine fever provided by the application adds the modified rhizomary peucedani inclusion compound and the modified quercetin, improves the bioavailability through modification and directly inhibits viral replicase;the medium-chain fatty acid glyceride destroys the lipid layer of the viral envelope and blocks the invasion of the virus;the organic acid sustained-release microcapsule continuously releases in the intestinal tract, reduces the pH to inhibit the activity of the virus and adjusts the intestinal flora;after enzymatic nanofication, the nano astragalus-houttuynia cordata complex improves the immune stimulation activity of astragalus polysaccharide and houttuynia cordata flavones and promotes the phagocytosis of macrophages and the secretion of interferon.

The invention provides a nasal mucosa vaccine adjuvant, a nasal mucosa vaccine, a preparation method and application, and belongs to the technical field of vaccine adjuvants. The invention provides a virus bionic nasal mucosa vaccine adjuvant, which takes nanoparticles as a carrier, a nucleic acid-like TLR agonist is loaded in the virus bionic nasal mucosa vaccine adjuvant, and a polysaccharide adjuvant is modified on the outer surface of the virus bionic nasal mucosa vaccine adjuvant; raw materials for preparing the nanoparticles comprise an amphiphilic polymer material and cationic lipid. From the structure, a shell of a nanoparticle of the nasal mucosa vaccine adjuvant simulates a virus envelope, a nucleic acid-like TLR agonist simulates virus nucleic acid, and the outer surface of the nanoparticle is modified with a polysaccharide adjuvant simulative virus glycoprotein; from the perspective of functions, the nasal mucosa vaccine adjuvant reengraves a virus infection time sequence, firstly activates a TLR2 / 4 pathway through a polysaccharide adjuvant to start mucosa immunity, and then activates an intracellular TLR3 pathway through a nucleic acid-like TLR agonist, so that dual-pathway synergistic interaction is realized, and the problem that mucosa and system immunity are disjointed by a traditional adjuvant is solved.

The invention provides an application of halofuginone in inhibiting Ebola virus infection, the invention discloses the anti-Ebola virus (inhibiting Ebola virus activity) ability of halofuginone for the first time, the halofuginone has small cytotoxicity (CC50 value is greater than 1 mu M), and experiments show that the combination of halofuginone and Ebola GP protein has strong affinity, and the halofuginone can be used for inhibiting Ebola virus infection. The compound inhibits virus infection by being combined with virus envelope protein GP, halofuginone can effectively inhibit replication of Ebola pseudovirus (IC50 value is 0.04 mu M) at low concentration, a new candidate small molecule compound is provided for developing a novel medicine for resisting Ebola virus infection, and the halofuginone has a wide application prospect in the field of Ebola virus treatment / prevention.

The application discloses a viral envelope protein, a lentivirus vector, a lentivirus and application thereof. The viral envelope protein is a mutant VSVG envelope protein, and the mutant VSVG envelope protein does not bind to a low-density lipoprotein receptor. The lentivirus vector comprises a nucleotide or a fragment thereof coding the envelope protein. The application specifically modifies the lentivirus envelope to adapt to the surface biological characteristics of NK cells and T cells, which is a core technical link for improving the transduction efficiency, reducing the activation threshold, and finally guaranteeing the safety and effectiveness of treatment. The application effectively enhances the efficiency and specificity of the lentivirus in NK cell and gamma-delta T cell infection by modifying the lentivirus envelope, has a wide application prospect in the field of adoptive immunotherapy, and provides practical basis and technical accumulation for developing the next generation of efficient and precise immune cell gene therapy tools.